Study Links Weight-Loss Drugs to Enhanced Kidney Health
A study published in the Lancet Diabetes & Endocrinology journal reveals that weight-loss drugs, specifically GLP-1 receptor agonists, can significantly improve kidney health by reducing the risk of kidney failure and worsening kidney function by up to 22%. The meta-analysis of 11 clinical trials involving over 85,000 participants also confirmed cardiovascular benefits, with a 14% reduction in cardiovascular events. These findings suggest that GLP-1 receptor agonists could play a crucial role in managing chronic kidney disease and cardiovascular conditions, potentially influencing future clinical guidelines.